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PCLINICAL RESEARCH Clinical Trials
Anti-Inflammatory Effects of Pioglitazone and/or
Simvastatin in High Cardiovascular Risk Patients
With Elevated High Sensitivity C-Reactive Protein
The PIOSTAT Study
Markolf Hanefeld, MD, PHD,* Nikolaus Marx, MD,† Andreas Pfützner, MD, PHD,‡
Werner Baurecht, MSC,§ Georg Lübben, MD, Efstrathios Karagiannis, MD, Ulf Stier, MD,*
Thomas Forst, MD‡
Dresden, Ulm, Mainz, Frechen, and Aachen, Germany
Objectives The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination ver-
sus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-
sensitivity C-reactive protein (hs-CRP) levels.
Background Low-grade inflammation is a pathogenic factor for atherosclerosis. High-sensitivity CRP, matrix metalloprotein-
ase (MMP)-9, and plasminogen activator inhibitor (PAI)-1 are markers of inflammation. Statins and peroxisome
proliferator-activated receptor (PPAR)- agonists lower inflammatory markers and reduce CVD in type 2 diabetes.
Methods In a 12-week, prospective, double-blind trial, 125 subjects were randomized to simvastatin or pioglitazone plus
placebo or a simvastatin/pioglitazone combination. We tested changes in hs-CRP by analysis of covariance. A
subgroup analysis was performed in patients with and without the metabolic syndrome (MetS). The correlation
between changes in hs-CRP and homeostasis model assessment (HOMA; a measure of insulin resistance) was
calculated with the Spearman’s rank test.
Results At baseline, there were no significant between-group differences. At 12 weeks, pioglitazone and simvastatin
monotherapies significantly reduced hs-CRP (3.64  2.42 mg/l to 2.48  1.77 mg/l and 3.26  2.02 mg/l to
2.81  2.11 mg/l) and the combination regimen had an additive effect (from 3.49  1.97 mg/l to 2.06  1.42
mg/l, p  0.001). For subgroups, the difference between monotherapy and combination therapy was only signif-
icant for simvastatin versus simvastatin plus pioglitazone in patients without MetS. Homeostasis model assess-
ment decreased in those receiving pioglitazone, and the correlation between changes in HOMA and hs-CRP was
significant (r  0.43; p  0.05). The PAI-1 decreased significantly in the pioglitazone groups only, and MMP-9
was also significantly lowered in the pioglitazone groups. No treatment-related serious adverse events occurred
in any group.
Conclusions Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin
in non-diabetic subjects with CVD and high hs-CRP. (J Am Coll Cardiol 2007;49:290–7) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.054fl
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dn the last decade, low-grade inflammation has been iden-
ified as a pivotal pathogenic factor in the development of
therosclerosis. Inflammatory activity has been shown to
redict myocardial infarction and stroke in patients with
re-existing cardiovascular disease (CVD). Numerous in-
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ponsored by Takeda. Drs. Lübben and Karagiannis are employees of Takeda.M
Manuscript received April 11, 2006; revised manuscript received August 24, 2006,
ccepted August 28, 2006.ammatory parameters, such as cell adhesion molecules,
ytokines, chemokines, and acute phase reactants, have been
dentified as valuable risk markers for the prediction of
ardiovascular events (1,2). The inflammatory phase pro-
ein, C-reactive protein (CRP), is associated with an in-
reased risk for CVD and stroke. It is frequently measured
n clinical practice and has been investigated extensively in
he context of atherosclerosis and vascular complications
3–6). Inflammatory activity is closely connected to the
etabolic syndrome (MetS) (7). In addition, matrix-
egrading matrix metalloproteinases (MMPs), such as
MP-9, have been implicated in plaque rupture through
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January 23, 2007:290–7 Simvastatin, Pioglitazone, and CVDheir capacity to thin the protecting fibrous cap of the
laque, thus rendering it more vulnerable (8). In fact,
MP-9 levels are elevated in patients with unstable plaques
9). Furthermore, peripheral blood levels of MMP-2 and -9
re elevated in patients with acute coronary syndromes (10).
Statins are currently the best known pharmaceutical
ntervention for CVD. In addition to their low-density
ipoprotein (LDL)-cholesterol–lowering effect, statins exert
nti-inflammatory actions by stimulating the expression of
eroxisome proliferator-activated receptor (PPAR)- (11–13).
urther pleiotropic effects are the inhibition of matrix
egradation by MMPs and the improvement of endothelial
unction by the up-regulation of nitric oxide synthesis
14,15).
In recent years, a close inter-relationship between inflam-
ation, insulin resistance, lipid disorders, the MetS, and the
evelopment of atherosclerosis has been identified in dia-
etic and non-diabetic patients. In this context, a new
harmaceutical class of drugs that targets insulin resistance,
he thiazolidinediones (TZDs) (PPAR- agonists), are now
idely used for the treatment of type 2 diabetes. Besides
heir beneficial effects on glucose and lipid metabolism,
ZDs have pleiotropic and anti-inflammatory properties.
linical studies have shown that they are able to reduce
nflammatory markers, such as CRP, MMP-9, macrophage
hemoattractant protein (MCP)-1, and soluble CD40L
16–19). However, of the degree to which the beneficial
ffects of TZDs might be due to improvements in diabetic
ontrol remains an open question. The TZDs inhibit the
roliferation of neointimal tissue in patients with and
ithout type 2 diabetes (20). This results in a decrease in the
ntima media thickness of carotid arteries in those with
iabetes (21–23). Results of a recent study of the TZD
ioglitazone (24) suggested that it reduces cardiovascular
nd points in patients with type 2 diabetes mellitus. Cur-
ently, it is good clinical practice, according to international
uidelines, to treat patients with CVD with statins. There
s, nevertheless, only scarce information on the benefits of
reatment with TZDs, alone or in combination with statins,
n patients with CVD and increased high-sensitivity (hs)-
RP levels. No data differentiating for subjects with and
ithout the MetS have been published from patients with
ype 2 diabetes and CVD.
In this study, we aimed to investigate the effect of
ioglitazone alone versus simvastatin alone versus pioglita-
one combined with simvastatin on different markers of
ow-grade inflammation in non-diabetic people with high
ardiovascular risk.
ethods
his phase III study was a prospective, double-blind,
ouble-dummy, 3-arm parallel-group trial evaluating the
nti-inflammatory effects of pioglitazone and/or simvastatin
reatment in patients with increased cardiovascular risk and
ctivated inflammation, defined as a CRP level 1 mg/l. (tudy subjects. A total of 135
atients, ages 30 to 70 years, with
VD (defined as medical history
f myocardial infarction; coro-
ary angiography evidence of
VD; unstable angina pectoris;
uplex-sonography of cervical or
eg vessels with atherosclerotic
ascular lesions; or electrocardio-
raphic evidence of ischemia,
troke, transient ischemic attack,
r peripheral arterial disease)
nd/or hypertension (blood pres-
ure 140/90 mm Hg or current
reatment with an antihyperten-
ive drug) and with an hs-CRP
evel in the range of1.0 mg/l to
10 mg/l, were randomly as-
igned to treatment with piogli-
azone and placebo, simvastatin
nd placebo, or pioglitazone in
ombination with simvastatin.
Main exclusion criteria were: previously known or newly
etected diabetes mellitus (fasting plasma glucose 126
g/dl according to the American Diabetes Association and
orld Health Organization definition) or chronic inflam-
atory diseases, statin therapy within the last 4 weeks,
ignificant hepatic (alanine aminotransferase 2.5-fold of
he gender-specific normal value) or renal (serum creatinine
2 mg/dl) disease, or congestive heart failure (New York
eart Association functional class I to IV).
The MetS was diagnosed according to the American
eart Association/National Heart Lung Blood Institute
efinition of 3 or more of the following 5 traits: waist
ircumference 102 cm (men) and 88 cm (women);
riglycerides 1.7 mmol/l; high-density lipoprotein
HDL)-cholesterol 1.03 mmol/l (men) and 1.3 mmol/l
women); blood pressure 130/85 mm Hg or treated with
ntihypertensive medication; or fasting plasma glucose5.6
mol/l (25).
tudy treatments. Treatment was started with 30 mg
ioglitazone and/or 20 mg simvastatin. After 2 weeks, the
ioglitazone dose was increased to 45 mg and the simva-
tatin dose was increased to 40 mg. The local ethics
ommittee approved the protocol, and all patients provided
ritten informed consent before enrollment in the study.
ssessments. Insulin, glucose, total cholesterol, HDL-
holesterol, LDL-cholesterol, triglycerides, MCP-1,
MP-9, and plasminogen activator inhibitor (PAI)-1 were
easured at study entry and after 12  1 weeks of study
edication. The hs-CRP was measured after 6  1 weeks
nd 12  1 weeks to obtain further information about the
ime course of the anti-inflammatory response. Insulin
ensitivity was estimated by homeostasis model assessment
Abbreviations
and Acronyms
CVD  cardiovascular
disease
HOMA  homeostasis
model assessment
hs-CRP  high-sensitivity
C-reactive protein
MCP  macrophage
chemoattractant protein
MetS  metabolic
syndrome
MMPs  matrix
metalloproteinases
PAI  plasminogen
activator inhibitor
PPAR  peroxisome
proliferator-activated
receptor
TZD  thiazolidinedionesHOMA) at baseline and after 12 weeks of treatment.
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Simvastatin, Pioglitazone, and CVD January 23, 2007:290–7All measurements were obtained in the morning after an
vernight fast. Patients were asked to refrain from coffee or
ea for at least 8 h before each study visit. Blood pressure
as measured with the patient in the sitting position for at
east 5 min. Height was measured at the first visit, and
eight was measured at the first visit and at each subsequent
ne.
iochemical parameters. High-sensitivity CRP was mea-
ured by immune turbidometry with latex particles (26).
The intra-assay coefficient of variation was 1.29% and the
nter-assay variability was 1.56%. Active PAI-1 antigen was
easured with enzyme immunoassay (Technoclone GmbH,
eidelberg, Germany). Real insulin was determined by
nzyme-linked immunoabsorbent assay (Anthos Mikrosys-
em, Krefeld, Germany). Plasma glucose was measured with
he glucose dehydrogenase method, cholesterol with the
holesterol oxidase method, HDL-cholesterol with the
HOD-PAP method after precipitation (Dia Sys Diagnos-
ic Systems, Holzheim, Germany), and triglycerides were
easured with GPO-PAP (DiaSys Diagnostic Systems).
nsulin resistance was calculated from the fasting insulin and
lucose values by means of HOMA analysis (HOMA score
nsulin [mU/l]  glucose [mmol/l]/22.5).
tatistical analyses. All statistical analyses were performed
ith SAS version 8.2 (SAS Institute Inc., Cary, North
arolina). No formal sample size calculation (as for a
onfirmatory trial) was performed.
All randomized patients who received at least 1 dose of
tudy medication were included in the intention-to-treat
nalysis of safety and tolerability. All patients with a
aseline value and at least 1 post-baseline assessment for
s-CRP 10 mg/l were included in the efficacy analysis.
Data are presented as arithmetic mean  SD for contin-
ous variables and as the number/proportion of patients for
ategorical variables. The geometric means for the primary
fficacy parameter hs-CRP are also provided. All inferential
tatistical analyses were performed in an exploratory sense
nd all p values 0.05 were interpreted as significant.
Treatment groups were compared at baseline using the
tudent t test for continuous variables and the chi-square
est for categorical variables. The statistical evaluation of
Baseline Clinical Characteristics of the 3 Treatm
Table 1 Baseline Clinical Characteristics of
Pioglitazon
(n  39)
Age (yrs), mean  SD 59.5  7.
Body mass index (kg/m2), mean  SD 30.8  4.
Men/women, n 13/26
Cardiovascular disease, n (%) 38 (97.4)
Hypertension, n (%) 36 (92.3)
RAS inhibition therapy, n (%) 23 (59.0)
Antithrombotic therapy, n (%) 6 (15.4)
Calcium channel blockers, n (%) 7 (17.9)
Metabolic syndrome*, n (%) 19 (48.7)*Defined according to the American Heart Association/National Heart, Lung,
RAS  renin-angiotensin system.hanges from baseline for the primary parameter was per-
ormed with an analysis of covariance (ANCOVA) model
ith fixed effect factors for treatment group and center and
ith baseline hs-CRP value as covariate. The natural
ogarithmic transformation was applied to the hs-CRP
alues because of their skewed distribution.
The F test was used to test the overall null hypothesis of
no difference between treatment groups.” Comparisons
etween all pairs of means were performed within the
NCOVA model by calculating simultaneous 95% confi-
ence intervals (CIs) of between-group treatment differ-
nces for the least square (LS)-means with the Tukey-
ramer procedure. The change from baseline within each
reatment group was assessed with 1-sample t tests for the
ypothesis of LS-mean  0.
For changes from baseline of secondary efficacy parame-
ers, 2-sided p values for within-group and between-group
reatment differences were calculated, with the t test proce-
ure for paired and independent samples. No transforma-
ions were applied to the secondary efficacy parameters.
The relationships between insulin resistance and hs-CRP
nd between insulin resistance and MMP-9 were assessed
ith the Spearman’s rank-order correlation coefficient.
esults
total of 135 patients were randomized to 1 of 3 treatment
roups. Three of these patients did not receive any dose of
tudy medication; thus, 132 patients were included in the
ntention-to-treat analysis of safety and tolerability. Forty-
our patients were treated with pioglitazone plus placebo
pioglitazone monotherapy), 43 patients with simavastatin
lus placebo (simvastatin monotherapy), and 45 patients
ith pioglitazone plus simvastatin (combination). Twenty-
wo patients (16.7%) discontinued the study prematurely.
even of the 132 patients were excluded from the efficacy
nalysis, because they had no hs-CRP value 10 mg/l
ither at baseline or at least 1 post-baseline. Thus, 125
atients (39 in the pioglitazone monotherapy group, 43 in
he simavastatin monotherapy group, and 43 in the piogli-
Groups
Treatment Groups
Simvastatin
(n  43)
Simvastatin Plus Pioglitazone
(n  43)
57.3  8.4 59.0  8.6
30.5  3.7 31.2  4.1
16/27 18/25
41 (95.3) 43 (100.0)
39 (90.7) 39 (90.7)
21 (48.8) 27 (62.8)
10 (23.3) 8 (18.6)
10 (23.3) 7 (16.3)
24 (55.8) 23 (53.5)ent
the 3
e
8
8and Blood Institute Scientific Statement 2005.
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January 23, 2007:290–7 Simvastatin, Pioglitazone, and CVDazone and simvastatin combination group) were included
n the efficacy analyses.
Demographic data and clinically relevant concomitant
edication for patients included in the efficacy analysis are
Figure 1 Changes in hs-CRP in the 3 Treatment Groups
Percentage changes from baseline (95% confidence interval) in high sensitiv-
ity C-reactive protein (hs-CRP) from baseline to 12 weeks in the 3 treatment
groups (solid bar  pioglitazone; open bar  simvastatin; hatched bar  pio-
glitazone plus simvastatin). All percentages represent 1 subtracted from the
antilogs of least square mean differences between baseline and week-12 log-
transformed values derived from the analysis of covariance model.
hanges in High-Sensitivity C-Reactive Protein (mg/l) in the 3 Trearoups Categorized by Patients Wi h and Without the Metabolic Sy
Table 2 Changes in High-Sensitivity C-Reactive Protein (mg/l)Groups Categorized by Patients With and Without the
Pioglitazone
Without the
Metabolic
Syndrome
(n  20)
With the
Metabolic
Syndrome
(n  19)
Witho
Meta
Synd
(n 
Baseline 2.80 1.60 (2.34) 4.52 2.84 (3.56) 2.73 1.
12 weeks 2.06 1.60 (1.57) 2.92 1.88 (2.34) 2.78 2.
Change 0.73 1.70 1.61 1.68 0.05 1.
exp (LS-means) 0.67 0.70 0.9
95% CIs (0.52–0.86) (0.55–0.88) (0.72–
p value 0.0025 0.0036 0.51
Pioglitazone vs.
Simvastatin*
Pioglitazone vs.
Simvastatin*
Piog
Simv
Pio
exp (difference
between LS-means)
0.73 0.94
Simultaneous
95% CIs
0.48–1.12 0.64–1.39 0
p value 0.1869 0.9315
alues are expressed as arithmetic mean  SD (geometric mean); antilogs of the least square
ovariance model of log-transformed data; lower values of the antilogs of the LS-means correspon
ifferences between the LS-means for each pairwise comparison (Tukey-Kramer), 2-sided 95% CIs and 2-s
or the antilogs of the difference between the LS-means correspond to “A better than B” when comparingresented in Table 1. All concomitant medications were
nchanged throughout the investigation. Treatment groups
ere comparable with respect to age; gender; presence of
VD, hypertension, and MetS; and antihypertensive and
ntithrombotic therapy. There were no statistically signifi-
ant differences between the treatment groups in any base-
ine parameters.
There were no significant differences in the baseline levels
f hs-CRP between the 3 groups. After 12 weeks of
reatment, hs-CRP levels were reduced from 3.64  2.42
g/l to 2.48  1.77 mg/l with pioglitazone monotherapy
nd from 3.26  2.02 mg/l to 2.81  2.11 mg/l with
imvastatin monotherapy (as illustrated in Fig. 1). Combi-
ation treatment with pioglitazone and simvastatin resulted
n an additive decrease in hs-CRP levels from 3.49  1.97
g/l to 2.06  1.42 mg/l after 12 weeks.
The exploratory p value related to the F test of testing the
lobal null-hypothesis of equal treatment means for the
hange from baseline with the log-transformed data was
 0.0143. Exploratory simultaneous 95% CIs according
o Tukey-Kramer for the antilogs of the differences between
he LS-means revealed significant differences (i.e., value “1”
ot included) for the pairwise comparison of simvastatin
onotherapy versus pioglitazone plus simvastatin in favor of
he combination therapy (antilog of the difference between
he LS means resulted in 1.40; 95% CIs ranged from 1.07 to
.84; p  0.0103). Statistics for hs-CRP for patients with
nd without the MetS by treatment group and pertinent
esults of the ANCOVA for the change from baseline after
2 weeks of treatment are given in Table 2. The percentage
eductions in hs-CRP levels in each treatment group are
tme
e 3 Treatment
bolic Syndrome
Simvastatin Simvastatin Plus Pioglitazone
With the
Metabolic
Syndrome
(n  24)
Without the
Metabolic
Syndrome
(n  20)
With the
Metabolic
Syndrome
(n  23)
0) 3.68 2.35 (2.86) 3.44 1.81 (2.95) 3.53 2.14 (2.98)
4) 2.83 2.17 (2.15) 2.06 1.52 (1.70) 2.06 1.35 (1.68)
0.85 1.56 1.38 1.61 1.47 2.00
0.74 0.59 0.56
(0.60–0.91) (0.46–0.76) (0.45–0.69)
0.0052 0.0001 0.0001
e vs.
Plus
ne*
Pioglitazone vs.
Simvastatin Plus
Pioglitazone*
Simvastatin vs.
Simvastatin Plus
Pioglitazone*
Simvastatin vs.
Simvastatin Plus
Pioglitazone*
1.25 1.55 1.32
74 0.85–1.84 1.01–2.38 0.92–1.90
0.3626 0.0429 0.1622
ans, 2-sided 95% confidence intervals (CIs), and 2-sided p values resulted from the analysis of
igher treatment effect, and higher values correspond to a lower treatment effect. *Antilogs of thetmenndro
in th
Meta
ut the
bolic
rome
19)
39 (2.4
09 (2.2
50
2
1.18)
21
litazon
astatin
glitazo
1.13
.74–1.
0.7586
(LS)-me
d to a hided p values resulted from the analysis of covariance model of log-transformed data; values 1
A versus B; values 1 correspond to “B better than A.”
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Simvastatin, Pioglitazone, and CVD January 23, 2007:290–7isplayed in Figure 1. Decreases in hs-CRP after 6 weeks of
reatment were comparable to the decreases after 12 weeks.
All results for the secondary efficacy parameters are
hown in Table 3. The MMP-9 baseline levels were
omparable among the 3 groups. At 12 weeks, there was
13.8% reduction in MMP-9 plasma levels with piogli-
hanges in Clinicalaram ters in the 3 Treatment Groups
Table 3 Changes in ClinicalParameters in the 3 Treatment Groups
Pioglitazone Simvastatin
Pioglitazone
Plus Simvastatin
hs-CRP (mg/l)
Baseline 3.64 2.42 3.26 2.02 3.49 1.97
12 weeks 2.48 1.77* 2.81 2.11 2.06 1.42*
MMP-9 (ng/ml)
Baseline 375.2 173.0 383.0 223.7 385.8 201.5
12 weeks 297.5 140.3* 477.5 250.9* 307.4 152.4*
MCP-1 (pg/ml)
Baseline 399.8 118.8 377.5 99.1 378.6 121.8
12 weeks 372.5 120.3 388.3 105.1 360.2 116.8
PAI-1 (ng/ml)
Baseline 30.5 23.5 35.2 43.5 30.3 26.5
12 weeks 18.8 16.9* 29.1 32.2 18.6 17.4*
Total cholesterol
(mmol/l)
Baseline 5.60 0.99 5.73 1.10 5.67 1.26
12 weeks 5.67 1.17 4.44 0.96* 4.43 0.95*
LDL-cholesterol
(mmol/l)
Baseline 3.50 0.94 3.60 1.01 3.68 1.10
12 weeks 3.56 1.04 2.32 0.88* 2.40 0.91*
HDL-cholesterol
(mmol/l)
Baseline 1.41 0.41 1.43 0.41 1.44 0.45
12 weeks 1.44 0.42 1.52 0.42* 1.53 0.45*
Triglycerides
(mmol/l)
Baseline 1.50 0.73 1.63 1.64 1.45 0.59
12 weeks 1.46 0.64 1.36 1.16 1.13 0.39*
Glucose (mmol/l)
Baseline 5.63 0.54 5.60 0.62 5.70 0.66
12 weeks 5.23 0.51* 5.56 0.55 5.50 0.68
HbA1c (%)
Baseline 5.47 0.46 5.43 0.40 5.58 0.40
12 weeks 5.37 0.45* 5.42 0.41 5.53 0.35
HOMA
Baseline 3.27 2.21 3.52 2.07 3.70 1.98
12 weeks 2.40 0.97* 3.63 1.60 2.81 1.15*
Body weight (kg)
Baseline 85.9 15.2 87.4 14.2 87.4 13.3
12 weeks 87.7 15.4* 87.4 14.7 88.6 12.8*
Body mass index
Baseline 30.6 4.7 30.5 3.6 31.1 4.1
12 weeks 31.3 5.2* 30.5 3.7 31.6 4.0*
alues are expressed as arithmetic mean SD and calculated for patients with measurements at
oth time points; *p  0.05 versus baseline; p values calculated with paired t tests.
Hb  hemoglobin; HDL  high-density lipoprotein; HOMA  homeostasis model assessment;
s-CRP  high-sensitivity C-reactive protein; LDL  low-density lipoprotein; MCP-1  macrophage
hemoattractant protein-1; MMP-9  matrixmetalloproteinases; nitric oxide (NO); PAI-1  plas-
inogen activator inhibitor.azone monotherapy (p  0.003) and a 13.2% reductionith the pioglitazone and simvastatin combination (p 
.004) (Fig. 2). In contrast, treatment with simvastatin
onotherapy resulted in a 41.5% increase in the levels of
MP-9 (p  0.019). After 12 weeks of treatment,
MP-9 levels were significantly lower in both pioglita-
one groups compared with the simvastatin monotherapy
roup (p  0.001).
The MCP-1 levels decreased in the pioglitazone-treated
atients (p  0.052). The PAI-1 levels decreased signifi-
antly after treatment with pioglitazone monotherapy (p 
.001) and after combined treatment with pioglitazone and
imvastatin (p  0.005). There were no significant changes
n either MCP- or PAI-1 with simvastatin monotherapy.
Significant improvements in total, LDL, and HDL
holesterol were achieved with treatment with simvastatin
onotherapy (p  0.05) and with combined simvastatin
nd pioglitazone treatment (p  0.05), whereas there were
mall increases in total cholesterol and LDL-cholesterol after
reatment with pioglitazone monotherapy. Triglycerides were
ignificantly decreased during combined treatment with pio-
litazone and simvastatin only (p  0.001) (Table 3).
There was a small but significant decrease (p 0.0001) in
asting plasma glucose levels in the pioglitazone mono-
herapy group and not in the simvastatin monotherapy
roup or the pioglitazone and simvastatin combination
roup. There were no episodes of hypoglycemia.
The HOMA decreased significantly during treatment
ith pioglitazone as monotherapy (p  0.003) and in
ombination with simvastatin (p  0.001) but remained
nchanged during simvastatin monotherapy. The decrease
n HOMA correlated with a decrease in MMP-9 (r 0.47;
 0.0001), PAI-1 (r  0.30; p  0.001), and hs-CRP
Figure 2 Changes in MMP-9, MCP-1, and
PAI-1 in the 3 Treatment Groups
Arithmetic mean  SEM for the relative change from baseline to 12 weeks in
matrix metalloproteinase-9 (MMP-9), macrophage chemoattractant protein-1
(MCP-1), and plasminogen activator inhibitor-1 (PAI-1) in the 3 treatment
groups (solid bars  pioglitazone; open bars  simvastatin; hatched bars 
pioglitazone plus simvastatin): *p  0.05 versus baseline; **p  0.01 versus
baseline; ***p  0.001 versus baseline.
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January 23, 2007:290–7 Simvastatin, Pioglitazone, and CVDr  0.23; p  0.05) in the total patient population. In the
ifferent treatment groups, the decrease in HOMA corre-
ated significantly with the decrease in hs-CRP in the
ioglitazone monotherapy group only (r  0.43; p 
.0059) (Fig. 3). This correlation also remained significant
hen excluding the single point on the extreme left of the
gure (Fig. 3). There was no significant correlation between
he improvement in hs-CRP and the changes in MCP-1
r  0.06; p  0.5388).
All treatment regimens were well tolerated in general.
reatment with pioglitazone as monotherapy and in com-
ination was associated with a higher incidence of periph-
ral edema (11.4% and 22.2%, respectively) than simvastatin
onotherapy (7.0%; p  0.7133 vs. pioglitazone mono-
herapy and p  0.0695 vs. pioglitazone combination
herapy) and with significant increases in body weight and
ody mass index (p  0.01) (Table 3). There was only 1
erious adverse event (1 patient in the pioglitazone mono-
herapy group was hospitalized owing to nephrolithiasis),
ut it was thought to be unrelated to study medication.
iscussion
ey findings. Our study in non-diabetic patients with
VD and elevated hs-CRP levels is the first to show a
ignificant anti-inflammatory effect of pioglitazone that was
omparable to that of 40 mg simvastatin. Furthermore, the
ombination of pioglitazone plus simvastatin had additive
ffects on hs-CRP, with a 40% reduction. Patients with
he MetS had higher level of hs-CRP, as already known. By
ubgroup analysis, the additive effect of pioglitazone was
nly significant for patients without the MetS. Because our
atients did not have diabetes, the anti-inflammatory effects
f pioglitazone seem to be unrelated to improvements in
Figure 3 Correlations of the Changes in
HOMA With the Changes of hs-CRP
Changes in homeostasis model assessment (HOMA) versus changes in high-
sensitivity C-reactive protein (hs-CRP) after 12 weeks of treatment. R  Spear-
man’s rank correlation coefficient; *p  0.05 for test of |R|  0; pioglitazone
(filled diamonds), p  0.0059; simvastatin (open triangles), p  0.9112; pio-
glitazone plus simvastatin (filled crosses), p  0.3848.lycemic control but might be related to improvements in nnsulin sensitivity. This is supported by the fact that we
ound a highly significant correlation between improve-
ents in HOMA and reductions in hs-CRP. The effects of
ioglitazone on insulin resistance have also been shown in
ther clinical studies (27,28). A rapid effect of rosiglitazone,
nother PPAR- agonist, on inflammatory biomarkers has
lso been shown in healthy non-diabetic subjects, promot-
ng the concept that TZDs also act independently of their
etabolic effects on low-grade inflammation (29). Our
ndings should be clinically relevant if, as suggested, low-
rade inflammation is a driving force in the development of
ascular complications.
A difference between groups was also observed in relation
o MMP-9, an enzyme that is of great importance for
laque stability. Pioglitazone, as monotherapy and in com-
ination, resulted in a significant reduction in MMP-9,
hereas simvastatin monotherapy produced a significant
ncrease. None of the treatment regimens had a significant
ffect on MCP-1. The HOMA was significantly improved
ith pioglitazone, as expected, whereas simvastatin had no
ffect. Simvastatin as monotherapy and in combination with
ioglitazone gave significant decreases in total cholesterol
nd LDL-cholesterol along with increases in HDL-
holesterol; this was not observed with pioglitazone mono-
herapy.
Statins have been shown to reduce cardiovascular events
n both primary and secondary prevention trials (30–33).
everal studies suggest that the observed clinical benefits of
tatin therapy might go beyond the reduction of LDL-
holesterol (31–34). Further to the improvement in lipid
etabolism, statins reduce low-grade inflammation, which
ight contribute to their anti-atherosclerotic effects. Data
rom prospective studies suggest that statin therapy might
lso prevent CVD by decreasing CRP levels (11,12,35,36).
ecently it has been shown that, in patients receiving
tatins, the reduction of LDL-cholesterol levels resulted in
slowed progression of vascular lesions whereas the addi-
ional lowering of hs-CRP-levels caused a regression of
therosclerotic plaques (11,12). In addition, statins have
een found to inhibit MMP-9 activity and secretion by
acrophages (37), to lower MMP-9 levels in patients with
ypercholesterolemia (38,39), and to decrease MMP-1 in
uman vascular endothelial cells (40). The MMP-9 levels
re elevated in patients with unstable plaques, and MMP-2
nd -9 levels contribute to acute coronary syndromes by
estabilizing the protective fibrous caps of the plaques (7).
he MMP-9 levels are also elevated in patients with
iabetes mellitus, and treatment with TZDs (e.g., pioglita-
one) seems to be effective in reducing the levels of this
nzyme (16,19,41). In our study, pioglitazone monotherapy
nd the combination of pioglitazone with simvastatin re-
ulted in a marked reduction in MMP-9, whereas the use of
imvastatin monotherapy for unknown reasons was associ-
ted with a significant increase. Although simvastatin had
o effect on insulin HOMA, we found a significant corre-
l
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Simvastatin, Pioglitazone, and CVD January 23, 2007:290–7ation between changes in insulin resistance as measured by
OMA and changes in MMP-9 levels.
In recent studies, treatment with TZDs was found to reduce
lasma MCP-1 in subjects with and without diabetes (17,19).
n this trial, neither simvastatin nor pioglitazone had a signif-
cant effect on the levels of MCP-1. Stimulation of PPAR-
educes plasma levels of CRP, MMP-9, MCP-1, and soluble
D40L (16,17,19,42); improves endothelial function (43,44);
nd reduces the intima media thickness of carotid arteries
21,23). In the recently published PROactive (PROspective
ioglitAzone Clinical Trial In macroVascular Events) study,
reatment with pioglitazone in patients with type 2 diabetes
esulted in a significant reduction in death, myocardial infarc-
ion, and stroke as aggregated events over a treatment period of
years (24). However, it should be noted that a meta-analysis
f phase 2 and 3 trials of muraglitazar, a PPAR-- agonist,
oncluded that mortality and major cardiovascular event rates
ncreased when compared with pioglitazone or placebo (45). It
as been suggested that the proinflammatory and atherogenic
ffects of CRP might be mediated by an increase in PAI-1
46,47). In this study, we found a significant decrease in plasma
AI-1 after treatment with pioglitazone monotherapy or in
ombination with simvastatin. Simvastatin monotherapy pro-
uced a nonsignificant decrease in PAI-1 levels.
afety. Throughout the study, both drugs were well toler-
ted and there was only 1 severe adverse event registered.
atients receiving pioglitazone showed a modest increase in
ody weight (mean 2 kg) that didn’t occur with simva-
tatin. It is important to underline the safety of pioglitazone
n terms of hypoglycemia (no events were reported), even in
eople with normal glucose tolerance.
onclusions. We found that pioglitazone and simvastatin
xerted anti-inflammatory effects in non-diabetic patients
ith CVD and elevated hs-CRP. Our study is the first to
how that combining pioglitazone with simvastatin in non-
iabetic patients with increased cardiovascular risk resulted
n an additive effect on low-grade inflammation, without a
ignificant increase in serious adverse events. The additive
ffect of pioglitazone on hs-CRP reduction was only signif-
cant for patients without the MetS. Although treatment
ith each drug in monotherapy significantly improved
everal risk markers for CVD, only the combination of
ioglitazone and simvastatin, with its synergistic effect,
eemed to have full anti-inflammatory potency and impact
n the whole risk profile of patients with CVD. Prospective
fficacy and safety trials are needed to determine whether a
ZD and statin combination reduces the incidence of
ardiovascular events in patients with high cardiovascular
isk and increased low-grade inflammation.
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